Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients

Hikaru Yamanaka, Katsuji Teruya, Mari Tanaka, Yoshimi Kikuchi, Takao Takahashi, Satoshi Kimura, Shinichi Oka

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine, From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%-10%] in vaccinated vs. 21.2% [CI: 13%-35%] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count > 200 cells/μL compared with those with a CD4 count <200 cells/μL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.

Original languageEnglish
Pages (from-to)167-173
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume39
Issue number2
Publication statusPublished - 2005 Jun 1

Fingerprint

Influenza Vaccines
HIV-1
Highly Active Antiretroviral Therapy
CD4 Lymphocyte Count
Viral Load
Confidence Intervals
Subunit Vaccines
Human Influenza
Antibody Formation
Vaccination
Vaccines
Prospective Studies
Antibodies
Incidence

Keywords

  • Antibody response
  • HIV-1
  • Influenza
  • Specific CD4
  • Vaccination

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Yamanaka, H., Teruya, K., Tanaka, M., Kikuchi, Y., Takahashi, T., Kimura, S., & Oka, S. (2005). Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes, 39(2), 167-173.

Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. / Yamanaka, Hikaru; Teruya, Katsuji; Tanaka, Mari; Kikuchi, Yoshimi; Takahashi, Takao; Kimura, Satoshi; Oka, Shinichi.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 39, No. 2, 01.06.2005, p. 167-173.

Research output: Contribution to journalArticle

Yamanaka, H, Teruya, K, Tanaka, M, Kikuchi, Y, Takahashi, T, Kimura, S & Oka, S 2005, 'Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients', Journal of Acquired Immune Deficiency Syndromes, vol. 39, no. 2, pp. 167-173.
Yamanaka, Hikaru ; Teruya, Katsuji ; Tanaka, Mari ; Kikuchi, Yoshimi ; Takahashi, Takao ; Kimura, Satoshi ; Oka, Shinichi. / Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. In: Journal of Acquired Immune Deficiency Syndromes. 2005 ; Vol. 39, No. 2. pp. 167-173.
@article{051bc976111042c2b5844b8541576ab9,
title = "Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients",
abstract = "Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine, From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1{\%} [95{\%} confidence interval (CI): 4{\%}-10{\%}] in vaccinated vs. 21.2{\%} [CI: 13{\%}-35{\%}] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count > 200 cells/μL compared with those with a CD4 count <200 cells/μL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.",
keywords = "Antibody response, HIV-1, Influenza, Specific CD4, Vaccination",
author = "Hikaru Yamanaka and Katsuji Teruya and Mari Tanaka and Yoshimi Kikuchi and Takao Takahashi and Satoshi Kimura and Shinichi Oka",
year = "2005",
month = "6",
day = "1",
language = "English",
volume = "39",
pages = "167--173",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients

AU - Yamanaka, Hikaru

AU - Teruya, Katsuji

AU - Tanaka, Mari

AU - Kikuchi, Yoshimi

AU - Takahashi, Takao

AU - Kimura, Satoshi

AU - Oka, Shinichi

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine, From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%-10%] in vaccinated vs. 21.2% [CI: 13%-35%] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count > 200 cells/μL compared with those with a CD4 count <200 cells/μL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.

AB - Influenza vaccine is recommended for HIV-1-infected patients. The present prospective study was conducted to evaluate the clinical efficacy and immunologic responses to the vaccine, From November 1 to December 27, 2002, 262 HIV-1-infected patients received a trivalent influenza subunit vaccine, whereas 66 did not. Influenza illness occurred in 16 vaccinated and 14 nonvaccinated patients (incidence = 6.1% [95% confidence interval (CI): 4%-10%] in vaccinated vs. 21.2% [CI: 13%-35%] in nonvaccinated persons, P < 0.001; relative risk = 0.29 [CI: 0.14-0.55]). Influenza vaccine provided clinically effective protection against influenza illness in HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count > 200 cells/μL compared with those with a CD4 count <200 cells/μL (P < 0.05). In contrast, in baseline antibody-positive patients, good antibody responses were observed irrespective of CD4 counts, like the healthy controls. Based on these results, annual vaccination is recommended. Specific CD4 responses correlated with HIV-1 viral load (VL), especially in patients treated with highly active antiretroviral therapy (HAART) compared with those without HAART (P < 0.01), although the clinical efficacy did not correlate with HIV-1 VL. HAART may enhance the immunologic efficacy of influenza vaccine.

KW - Antibody response

KW - HIV-1

KW - Influenza

KW - Specific CD4

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=19644367545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19644367545&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 167

EP - 173

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -